Jain Rita
SEC-identified person · CIK 1707797 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Celldex Therapeutics, Inc. CLDX | Director | filed 2023–2026 |
| First Tracks Biotherapeutics, Inc. TRAX | Director | filed 2026–2026 |
| Cerecor Inc. CERC | Director | filed 2025–2026 |
| Anaptysbio, INC ANAB | Director | filed 2023–2026 |
| SAB Biotherapeutics, Inc. SABS | Director | filed 2026–2026 |
| Provention Bio, Inc. PRVB] | Director | filed 2023–2023 |
| Chemocentryx, Inc. CCXI | Director · EVP, Chief Medical Officer | filed 2019–2022 |
| Immunovant, Inc. IMVT | Chief Medical Officer | filed 2021–2021 |
| Akebia Therapeutics, Inc. AKBA | SVP, Chief Medical Officer | filed 2017–2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.